Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - norethisterone acetate, quantity: 4.8 mg (equivalent: estradiol, qty 50 microgram; equivalent: norethisterone acetate, qty 250 microgram); estradiol, quantity: 0.512 mg (equivalent: estradiol, qty 50 microgram) - drug delivery system, transdermal - excipient ingredients: oleic acid; dipropylene glycol; povidone; polyethylene terephthalate; ethylene/vinyl acetate copolymer; polyvinylidene flouride; ethyl acetate; ethanol; toluene; acrylates/va copolymer; polytrimethylhydrosilylsiloxane; xylene; ammonia; 1,1,1-trimethyl-n-(trimethylsilyl)silanamine; dimeticonol - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. for prevention of postmenopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estalis continous should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - norethisterone acetate, quantity: 2.7 mg (equivalent: estradiol, qty 50 microgram; equivalent: norethisterone acetate, qty 140 microgram); estradiol, quantity: 0.62 mg (equivalent: estradiol, qty 50 microgram) - drug delivery system, transdermal - excipient ingredients: oleic acid; dipropylene glycol; povidone; polytrimethylhydrosilylsiloxane; xylene; ammonia; toluene; 1,1,1-trimethyl-n-(trimethylsilyl)silanamine; dimeticonol; polyethylene terephthalate; polyvinylidene flouride; ethyl acetate; ethanol; acrylates/va copolymer; ethylene/vinyl acetate copolymer - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. for prevention of postmenopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estalis continous should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Irland - Englisch - HPRA (Health Products Regulatory Authority)

novo nordisk a/s - estradiol anhydrous; norethisterone acetate - film-coated tablet - 1 mg / 0.5 milligram(s) - progestogens and estrogens, fixed combinations; norethisterone and estrogen

Irland - Englisch - HPRA (Health Products Regulatory Authority)

novo nordisk a/s - estradiol; norethisterone acetate; estradiol - film-coated tablet - %v/v - progestogens and estrogens, fixed combinations; norethisterone and estrogen

Belgien - Englisch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

impexeco - estradiol hemihydrate; norethisterone acetate - film-coated tablet - 1 mg - 0,5 mg - estradiol hemihydrate 1.03 mg; norethisterone acetate 0.5 mg - norethisterone and estrogen

Belgien - Englisch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

novo nordisk pharma sa-nv - estradiol hemihydrate 1,03 mg - eq. estradiol 1 mg (white tablet); norethisterone acetate 1 mg (white tablet); estradiol hemihydrate 1,03 mg - eq. estradiol 1 mg (red tablet) - film-coated tablet - 1 mg + 1 mg - 1 mg - estradiol hemihydrate 1.03 mg; estradiol hemihydrate 1.03 mg; norethisterone acetate 1 mg - norethisterone and estrogen

Irland - Englisch - HPRA (Health Products Regulatory Authority)

theramex ireland limited - estradiol hemihydrate; norethisterone acetate - transdermal patch - 50 microg/24h +170 microgram(s)/24 hours - natural and semisynthetic estrogens, plain; estradiol, combinations

Belgien - Englisch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

orifarm - estradiol hemihydrate; norethisterone acetate - film-coated tablet - 1 mg - 0,5 mg - estradiol hemihydrate; norethisterone acetate 0.5 mg - norethisterone and estrogen

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - norethisterone acetate, quantity: 4.8 mg (equivalent: estradiol hemihydrate, qty 0.806 mg; equivalent: norethisterone acetate, qty 250 microgram/24 h); estradiol, quantity: 0.512 mg (equivalent: estradiol, qty 50 microgram/24 h; equivalent: estradiol hemihydrate, qty 0.529 mg) - drug delivery system, transdermal - excipient ingredients: oleic acid; povidone; dipropylene glycol; polytrimethylhydrosilylsiloxane; xylene; ammonia; toluene; 1,1,1-trimethyl-n-(trimethylsilyl)silanamine; dimeticonol; polyethylene terephthalate; polyvinylidene flouride; ethyl acetate; ethanol; acrylates/va copolymer; ethylene/vinyl acetate copolymer - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - norethisterone acetate, quantity: 2.7 mg (equivalent: estradiol hemihydrate, qty 0.806 mg; equivalent: norethisterone acetate, qty 140 microgram/24 h); estradiol, quantity: 0.62 mg (equivalent: estradiol, qty 50 microgram/24 h; equivalent: estradiol hemihydrate, qty 0.64 mg) - drug delivery system, transdermal - excipient ingredients: povidone; oleic acid; dipropylene glycol; polytrimethylhydrosilylsiloxane; xylene; ammonia; toluene; 1,1,1-trimethyl-n-(trimethylsilyl)silanamine; dimeticonol; ethyl acetate; ethanol; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; ethylene/vinyl acetate copolymer - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.